`Patent No. 9,539,218
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`MYLAN PHARMACEUTICALS INC.,
`Petitioner,
`
`v.
`BAYER INTELLECTUAL PROPERTY GMBH,
`Patent Owner.
`
`
`
`Case No. IPR2018-01143
`Patent No. 9,539,218
`
`
`
`PATENT OWNER’S MANDATORY NOTICES
`UNDER 37 C.F.R. § 42.8(a)(2)
`
`
`Patent Owner Bayer Intellectual Property GmbH hereby submits the
`
`
`
`following mandatory notices pursuant to 37 C.F.R. § 42.8(a)(2).
`
`A. Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1))
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Patent Owner identifies Bayer
`
`Intellectual Property GmbH (the Patent Owner), Bayer AG (an exclusive licensee),
`
`and Janssen Pharmaceuticals, Inc. (an exclusive sublicensee).
`
`In addition, out of an abundance of caution, the Patent Owner notes that
`
`counsel for Bayer Corporation has been involved in this proceeding, and further
`
`notes that Bayer Intellectual Property GmbH and Bayer Corporation are wholly-
`
`
`
`
`owned subsidiaries of Bayer AG, and that Janssen Pharmaceuticals, Inc. is a
`
`Case IPR2018-01143
`Patent No. 9,539,218
`
`wholly-owned subsidiary of Johnson & Johnson.
`
`B. Related Matters (37 C.F.R. § 42.8(b)(2))
`
`The Patent Owner identifies the following matters that may affect, or may be
`
`affected by, a decision in this proceeding:
`
` Bayer Intellectual Property GmbH, et al. v. Taro Pharmaceutical
`Industries Ltd., et al., No. 1:17-cv-462-RGA (D. Del), a proceeding in
`which Patent Owner has asserted U.S. Patent No. 9,539,218 (“the ’218
`patent”) against Petitioner and other defendants. The case Patent
`Owner originally asserted against Petitioner regarding the ’218 patent,
`Bayer Intellectual Property GmbH, et al. v. Mylan Pharmaceuticals
`Inc., No. 1:17-cv-584-RGA (D. Del.), was consolidated into the
`above-referenced action, along with eight other cases in which Patent
`Owner has asserted the ’218 patent: (1) Bayer Intellectual Property
`GmbH, et al. v. Aurobindo Pharma Limited, et al., No. 1:17-cv-483-
`RGA (D. Del.); (2) Bayer Intellectual Property GmbH, et al. v. Micro
`Labs Ltd., et al., No. 1:17-cv-560-RGA (D. Del.); (3) Bayer
`Intellectual Property GmbH, et al. v. Sigmapharm Laboratories, LLC,
`No. 1:17-cv-648-RGA (D. Del.); (4) Bayer Intellectual Property
`GmbH, et al. v. Alembic Pharmaceuticals Limited, et al., No. 1:17-cv-
`675-RGA (D. Del.); (5) Bayer Intellectual Property GmbH, et al. v.
`InvaGen Pharmaceuticals, Inc., No. 1:17-cv-812-RGA (D. Del.); (6)
`Bayer Intellectual Property GmbH, et al. v. Lupin Limited, et al., No.
`1:17-cv-1047-RGA (D. Del.); (7) Bayer Intellectual Property GmbH,
`et al. v. Breckenridge Pharmaceutical, Inc., No. 1:17-cv-1129-RGA
`
`
`
`
`
`Case IPR2018-01143
`Patent No. 9,539,218
`
`(D. Del.); and (8) Bayer Intellectual Property GmbH, et al. v. Torrent
`Pharmaceuticals, Limited, et al., No. 1:17-cv-1163-RGA (D. Del.).
`
`C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3))
`
`Patent Owner designates the following counsel:
`
`Lead Counsel:
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Back-up Counsel:
`
`Dov P. Grossman (Reg. No. 72,525)
`Williams & Connolly LLP
`
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5812
`Facsimile: 202-434-5029
`
`Ben Picozzi (Reg. No. 76,862)
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Direct Phone: 202-434-5266
`Facsimile: 202-434-5029
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`A power of attorney appointing these attorneys to transact all business in this
`
`proceeding are submitted together with this mandatory notice information.
`
`D. Service Information (37 C.F.R. § 42.8(b)(4))
`
`Counsel for Patent Owner submits the following service information:
`
`
`(i)
`
`Electronic mail address:
`
`
`(ii) Postal mailing address:
`
`dgrossman@wc.com
`bpicozzi@wc.com
`
`
`Dov P. Grossman
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington D.C. 20005
`
`
`
`
`
`
`Case IPR2018-01143
`Patent No. 9,539,218
`
`(iii) Hand-delivery address: Dov P. Grossman
`Williams & Connolly LLP
`725 Twelfth Street, N.W.
`Washington D.C. 20005
`
`
`
`(iv) Telephone number:
`
`Facsimile number:
`
`(v)
`
`
`
`
`
`202-434-5812
`
`202-434-5029
`
`
`Counsel for Patent Owner consents to electronic service by email at:
`
`dgrossman@wc.com and bpicozzi@wc.com.
`
`
`
`Dated: June 12, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`
`
`/Dov P. Grossman/
`Dov P. Grossman
`Reg. No. 72,525
`Williams & Connolly LLP
`725 Twelfth St. NW
`Washington, DC 20005
`Telephone: 202-434-5812
`Facsimile: 202-434-5029
`Email: dgrossman@wc.com
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case IPR2018-01143
`Patent No. 9,539,218
`
`CERTIFICATE OF SERVICE
`(37 C.F.R. § 42.6(e))
`The undersigned hereby certifies that the document above was served on
`
`
`
`
`
`this 12th day of June, 2018, on the Petitioner by delivering a copy via electronic
`
`mail to the following individuals at the email addresses below:
`
`Steven W. Parmelee
`Reg. No. 31,990
`parmelee@wsgr.com
`
`Michael T. Rosato
`Reg. No. 52,182
`mrosato@wsgr.com
`
`Jad A. Mills
`Reg. No. 63,344
`jmills@wsgr.com
`
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue
`Suite 5100
`Seattle, WA 98104-7036
`P: 206-883-2542
`F: 206-883-2699
`
`
`
`Date: June 12, 2018
`
`
`
`
`
`
`By: /Dov P. Grossman/
`Dov P. Grossman
`Lead Counsel for Patent Owner
`Registration No. 72,525
`
`